TheraRadar
← Back
Data updated: Mar 29, 2026

ARROWHEAD

Infectious DiseaseCardiovascularRespiratory
Pharma

ARROWHEAD is a pharmaceutical company focused on Infectious Disease, Cardiovascular, Respiratory. Key products include REDEMPLO.

2025
Since
1
Drugs
-
Trials
1
Approved (2yr)

Key Drugs

REDEMPLO
plozasiran sodium
ApoC-III mRNA 1 indications · 2025

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

REDEMPLO 2025-11-18
Type 1 - New Molecular Entity
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Infectious Disease 42%
0 drugs Phase 2: 6 Phase 1: 3
Cardiovascular 31%
0 drugs Phase 3: 2 Phase 2: 1 Phase 1: 1
Respiratory 19%
0 drugs Phase 2: 1 Phase 1: 5
Metabolic 6%
0 drugs Phase 1: 2
Neurology 3%
0 drugs Phase 1: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

GE HEALTHCARE specialty
Infectious Disease, Neurology, Cardiovascular, Respiratory
Merck big-pharma
Infectious Disease, Cardiovascular, Metabolic
Novo Nordisk big-pharma
Metabolic, Cardiovascular, Infectious Disease, Neurology
LEDERLE big-pharma
Infectious Disease, Cardiovascular, Neurology, Respiratory
Johnson & Johnson big-pharma
Infectious Disease, Cardiovascular, Metabolic